METTL1-mediated m7G hypomethylation promotes tsRNA biogenesis in prostate cancer [108], and m7G-modified tsRNA-LysTTT catalyzed by METTL1 enhances bladder cancer malignancy [109]. The gene discussed is METTL1; the disease is prostate cancer.